ALSO NOTED: FDA rejects Questcor application; Agency wants more Merck data; Cell Therapeutics sub names officers; NICE rejects

> Questcor Pharmaceuticals says the FDA has issued a "not approvable" letter for H.P. Acthar Gel (repository corticotropin injection) for the treatment of infantile spasms. Release

> Merck says that the FDA has asked for more data on Emend, an intravenous version of a drug designed to relieve nausea in chemo patients. An oral version has already been approved and Merck says a final decision should come six months after it submits the added data. Report

> Regulators say that MedImmune's inhalable flu vaccine is effective in children under five but may increase the risk of repiratory illness. Report

> Chutes & Ladders: Cell Therapeutics has named a management team for its recently-formed subsidiary Aequus BioPharma. Carl J. March, Ph.D., former senior vice president at Immunex, has been chosen as president and CEO. Release

> The UK's National Institute for Health and Clinical Excellence has once again rejected Erbitux as a therapy for head and neck cancer, saying that it no better or cheaper than existing therapies. Report

> Canada's Biovail has been notified by the SEC that the agency is considering taking action against the company for accounting and disclosure violations. Report

> Validus Pharmaceuticals has acquired Marplan (isocarboxazid) from Oxford Pharmaceuticals. Release

> The FDA has approved a new dosage of Merck's FOSAMAX PLUS D. Release

And Finally…The mammography rate in the U.S. has been steadily declining in recent years. Release